NYSE • Last print unknown ago
$23.45—Stale · unknown old
Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2
IBD and MarketWatch's sixth annual survey honors most trusted financial companies
Stone secures IBD financing to offer credit to businesses in the Amazon
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data